Dr. David Hong

Dr. David S. Hong

  • Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program), and an Associate Vice President of Clinical Research at University of Texas MD Anderson Cancer Center
  • Noteworthy in forming one of the largest and most innovative Phase 1 clinical trial units in the world, with over 1200 patients enrolled in clinical trials in FY2018 and over 228 active ongoing clinical trials
  • Has been the Principal Investigator of over 100 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute
  • Has been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib,and larotrectinib that have led to FDA approval
  • An expert on c-Met ,NTRK, and KRAS and has led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial
  • Awarded with the ASCO Young Investigator Award, the Jesse Jones award, Best Boss award at MD Anderson, Irwin Krakoff Award for Clinical Research and the Gerald P. Bodey award for education and Mentor of the year award in the Division of Cancer Medicine, MD Anderson